Naphthalimide derivatives with therapeutic characteristics: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 3, 2013, Pages 299-317

  Kamal, Ahmed ^a   Bolla, Narasimha Rao ^a   Srikanth, Pandala Sindayla ^a   Srivastava, Ajay Kumar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Antitumor activity; DNA intercalation; Heterocyclic conjugates; Histone deacetylase inhibitor; Naphthalimides; PARP inhibitor; Topoisomerase I inhibition

Indexed keywords

1 METHYLPIPERAZINE; 3 NITRONAPHTHALIMIDE; 4 AMINO 1,8 NAPHTHALIMIDE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AMONAFIDE; ARISTOLOCHIC ACID; BIBENILONE; BISNAFIDE; CG 630; CYCLOHEXIMIDE; CYTARABINE; ELINAFIDE; GK 01385; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITONAFIDE; NAPHTHALIMIDE DERIVATIVE; PHOTOSENSITIZING AGENT; PLATINUM COMPLEX; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; SELENIUM DERIVATIVE; TILORONE; UNBS 3157; UNBS 5162; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; AUTOPHAGY; BECKER NEVUS; BREAST CANCER; CANCER CELL CULTURE; CANCER RESEARCH; DNA BINDING; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DUCHENNE MUSCULAR DYSTROPHY; ESOPHAGUS CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; GLIOSARCOMA; GRAM NEGATIVE BACTERIUM; HEAD AND NECK CANCER; HEART INFARCTION; HIGH THROUGHPUT SCREENING; HORMONAL THERAPY; HUMAN; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATORY DISEASE; ISCHEMIA; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; LYSOSOME MEMBRANE; NEOPLASM; NEUROLOGIC DISEASE; PATENT; PHARMACOPHORE; PLASMODIUM; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RESPIRATORY TRACT DISEASE; REVIEW; VIRUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIPROTOZOAL AGENTS; ANTIVIRAL AGENTS; DRUG DESIGN; HUMANS; INTERCALATING AGENTS; NAPHTHALIMIDES; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874034173     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.746313     Document Type: Review

References (95)

1. Brana M, Castellano J, Moran M, et al. Synthesis, structure and anti-tumor activity of new benz [d, e] isoquinoline-1, 3-diones. Arzneimittelforschung 1995;45:1311-18
2. Bailly C, Carrasco C, Joubert A, et al. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono-and bisfuronaphthalimides. Biochemistry 2003;42:4136-50
3. Li X, Lin Y, Wang Q, et al. The novel anti-tumor agents of 4-triazol-1, 8-naphthalimides: Synthesis, cytotoxicity, DNA intercalation and photocleavage. Eur J Med Chem 2011;46:1274-9
4. Kamal A, Reddy B, Reddy G, et al. Design and synthesis of C-8 linked pyrrolobenzodiazepine-naphthalimide hybrids as anti-tumour agents. Bioorg Med Chem Lett 2002;12:1933-5
5. Filosa R, Peduto A, Micco SD, et al. Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. Bioorg Med Chem 2009;17:13-24
6. Muth M, Hoerr V, Glaser M, et al. Anti-trypanosomal activity of quaternary naphthalimide derivatives. Bioorg Med Chem Lett 2007;17:1590-3
7. Chang SC, Archer BJ, Utecht RE, et al. 4-Alkylamino-3-bromo-N-alkyl-1, 8-naphthalimides: New photochemically activatable anti-viral compounds. Bioorg Med Chem Lett 1993;3:555-6
8. Chanh TC, Lewis DE, Judy MM, et al. Inhibition of retrovirus-induced syncytium formation by photoproducts of a brominated 1, 8-naphthalimide compound. Antiviral Res 1994;25:133-46
9. da Settimo A, Primofiore G, Ferrarini PL, et al. Reinvestigation of reductive butylation of aminophthalimides: New compounds with local anesthetic activity. Eur J Med Chem 1989;24:263-70
10. Andricopulo AD, Muller LA, Cechinel Filho V, et al. Analgesic activity of cyclic imides: 1, 8-naphthalimide and 1, 4, 5, 8-naphthalenediimide derivatives. Il Farmaco 2000;55:319-21
11. Clark R, Weinhardt K, Berger J, et al. N-(quinuclidin-3-YL)-1, 8,-naphthalimides with 5-HT3 receptor antagonist and 5-HT4 receptor agonist properties. Bioorg Med Chem Lett 1993;3:1375-8
12. Berque-Bestel I, Soulier JL, Giner M, et al. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors. J Med Chem 2003;46:2606-20
13. Duke RM, Veale EB, Pfeffer FM, et al. Colorimetric and fluorescent anion sensors: An overview of recent developments in the use of 1, 8-naphthalimide-based chemosensors. Chem Soc Rev 2010;39:3936-53
14. Dorlars A, Schellhammer CW, Schroeder J. Heterocycles as structural units in new optical brighteners. Angew Chem Int Ed Engl 1975;14:665-79
15. Wolfbeis OS. Materials for fluorescence-based optical chemical sensors. J Mater Chem 2005;15:2657-69
16. Xu Z, Yoon J, Spring DR. A selective and ratiometric Cu2+ fluorescent probe based on naphthalimide excimer-monomer switching. Chem Commun 2010;46:2563-5
17. Xu Z, Qian X, Cui J. Colorimetric and ratiometric fluorescent chemosensor with a large red-shift in emission: Cu (II)-only sensing by deprotonation of secondary amines as receptor conjugated to naphthalimide fluorophore. Org Lett 2005;7:3029-32
18. Stewart WW. Functional connections between cells as revealed by dye-coupling with a highly fluorescent naphthalimide tracer. Cell 1978;14:741-59
19. Ingrassia L, Lefranc F, Kiss R, et al. Naphthalimides and azonafides as promising anticancer agents. Curr Med Chem 2009;16:1192-213
20. Lv M, Xu H. Overview of naphthalimide analogs as anticancer agents. Curr Med Chem 2009;16:4797-813
21. Stevenson KA, Yen SF, Yang NC, et al. A substituent constant analysis of the interaction of substituted naphthalene monoimides with DNA. J Med Chem 1984;27(12):1677-82
22. Brana M, Ramos A. Naphthalimides as anticancer agents: Synthesis and biological activity. Curr Med Chem Anticancer Agents 2001;1:237-55
23. Heron M, Hoyert DL, Murphy SL, et al. National vital statistics reports. Nat Vit Stat Rep 2009;57:1-136.
24. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002;2:188-200
25. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204
26. Arcamone FM, Animati F, Barbieri B, et al. Synthesis, DNA-binding properties, and anti-tumor activity of novel distamycin derivatives. J Med Chem 1989;32:774-8
27. Brana MF, Cacho M, Garcia MA, et al. New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, anti-tumor activity, molecular modeling, and DNA binding properties. J Med Chem 2004;47:1391-9
28. Zee-Cheng RKY, Cheng C. N-(Aminoalkyl) imide anti-neoplastic agents. Synthesis and biological activity. J Med Chem 1985;28:1216-22
29. Chen Z, Liang X, Zhang H, et al. A new class of naphthalimide-based anti-tumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem 2010;53:2589-600
30. Xie L, Cui J, Qian X, et al. 5-Non-amino aromatic substituted naphthalimides as potential anti-tumor agents: Synthesis via suzuki reaction, anti-proliferative activity, and DNA-binding behavior. Bioorg Med Chem 2011;19:961-7
31. Li X, Lin Y, Yuan Y, et al. Novel efficient anticancer agents and DNA intercalators of 1, 2, 3-triazol-1, 8-naphthalimides: Design, synthesis and biological activity. Tetrahedron 2011;67:2299-304
32. Yin H, Zhu W, Xu Y, et al. Novel aliphatic N-oxide of naphthalimides as fluorescent markers for hypoxic cells in solid tumor. Eur J Med Chem 2011;46:3030-7
33. Azeeza S, Bharathi E, Malik M, et al. Search for new and novel chemotherapeutics for the treatment of human malignancies. Mini Rev Med Chem 2010;10:405-35
34. Yen SF, Gabbay EJ, Wilson WD. Interaction of aromatic imides with DNA. 1. Spectrophotometric and viscometric studies. Biochemistry 1982;21:2070-6
35. Kamal A, Adil S, Tamboli JR, et al. Synthesis and anticancer activity of phthalimido and naphthalimido substituted dihydropyrimidone conjugates. Lett Drug Des Discov 2008;5:261-70
36. Kamal A, Adil S, Tamboli JR, et al. Synthesis of coumarin linked naphthalimide conjugates as potential anticancer and anti-microbial agents. Lett Drug Des Discov 2009;6:201-9
37. Kamal A. Novel naphthalimide-benzimidazole hybrids as potential anti-tumour agents and process for the preparation thereof. WO2009110000 ; 2009
38. Tumiatti V, Milelli A, Minarini A, et al. Design, synthesis, and biological evaluation of substituted naphthalene imides and diimides as anticancer agent¥. J Med Chem 2009;52:7873-7
39. Van Quaquebeke E, Mahieu T, Dumont P, et al. 2, 2, 2-trichloro-N-({2-[2- (dimethylamino) ethyl]-1, 3-dioxo-2, 3-dihydro-1 H-benzo [de] isoquinolin-5-yl} carbamoyl) acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent anti-tumor activity. J Med Chem 2007;50:4122-34
40. Perez JM, Lopez-Solera I, Montero EI, et al. Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis (naphthalimide) complexes. J Med Chem 1999;42:5482-6
41. Ott I, Qian X, Xu Y, et al. A gold (I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting anti-proliferative agent and angiogenesis inhibitor. J Med Chem 2009;52:763-70
42. Peduto A, Pagano B, Petronzi C, et al. Design, synthesis, biophysical and biological studies of trisubstituted naphthalimides as G-quadruplex ligands. Bioorg Med Chem 2011;19:6419-29
43. Wang K, Wang Y, Yan X, et al. DNA binding and anticancer activity of naphthalimides with 4-hydroxyl-alkylamine side chains at different lengths. Bioorg Med Chem Lett 2012;22:937-41
44. Zhao L, Li J, Li Y, et al. Selenium-containing naphthalimides as anticancer agents: Design, synthesis and bioactivity. Bioorg Med Chem 2012;20:2558-63
45. Xie S, Zhang Y, Li Q, et al. 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis 2012;17:725-37
46. Mohammadkhodaei Z, Mokhtari J, Nouri M. Novel anti-bacterial acid dyes derived from naphthalimide: Synthesis, characterisation and evaluation of their technical properties on nylon 6. Color Tech 2010;126:81-5
47. Tischer M, Sologub L, Pradel G, et al. The bisnaphthalimides as new active lead compounds against Plasmodium falciparum. Bioorg Med Chem 2010;18:2998-03
48. Zhang Y, Feng S, Wu Q, et al. Microwave-assisted synthesis and evaluation of naphthalimides derivatives as free radical scavengers. Med Chem Res 2011;20:752-9
49. Mata MA, Satterly N, Versteeg GA, et al. Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol 2011;7:712-19
50. Kamal A, Rondla R, Khanna G, et al. Pyrrolo [2, 1-c][1, 4] benzodiazepinenapthalimide conjugates linked through piperazine moiety and process for preparation thereof. WO2006003670 ; 2006
51. Kamal A, Ramu R, Tekumalla V, et al. Preparation of pyrrolo[2,1-c][1,4] benzodiazepine-aphthalimide conjugates linked through piperazine moiety useful as antitumor agents. IN2004DE01218 ; 2004
52. Gazzard L. Heterocyclic-substituted bis-1, 8 naphthalimide compounds, antibody drug conjugates, and methods of use. WO2007064345 ; 2007
53. Ferri N, Radice T, Antonino M, et al. Synthesis, structural and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. Bioorg Med Chem 2011;19:5291-9
54. Lahav R, Patterson PH. Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity. US20060094676 ; 2006
55. Hellstrand K, Hermodsson S, Thoren F, et al. Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis. WO2006039545 ; 2006
56. Hellstrand K, Hermodsson S, Thoren F, et al. Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis. US20060079510 ; 2006
57. Scotto KA, Mandola M. Use of PARP-1 inhibitors. WO2007062413 ; 2007
58. Biro A, Katzir Z. Combination of an Aminoglycoside Antibiotic and a PARP. Inhibitor. WO2008050339 ; 2008
59. Kerr DA, Kaplin AI, Krishnan C. Use of IL-6 in the diagnosis and treatment of neuroinflammatory conditions. WO2008016707 ; 2008
60. Brownlee M. Use of PARP inhibitors for prevention and treatment of diabetic and insulin resistance complications. US20080161255 ; 2008
61. Krawczyk P, Aten JA, Kanaar R, et al. Method of treating cancer. WO2010082821 ; 2010
62. Chowdhury D. Mir-182 in the diagnosis and treatment of cancer. US20110178163 ; 2011
63. O'malley BW, Abuzeid WM, Li D. Anti-neoplastic combination therapy comprising co-disruption pathway and mre11/rad50/nbs1 complex and compositon thereof. WO2009114459 ; 2009
64. Carroll S, Hernando JIM, Malancona S, et al. Naphthalimide derivatives as antiviral agents. WO2006027628 ; 2006
65. Gopalsamy A, Lim K, Ellingboe JW, et al. Identification of [(naphthalene-1-carbonyl)-amino]-acetic acid derivatives as nonnucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett 2004;14:4221-4
66. Levenson JM, Sweatt JD. Histone deacetylase inhibitors and cognitive applications. US20060018921 ; 2006
67. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007;321:892-901
68. Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007;117:3765
69. Gruber PJ, Epstein JA. Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury. WO2006060382 ; 2006
70. De la porte S, Israel M, Voisin V, et al. Use of a histone deacetylase inhibitor for treating muscular dystrophies. US20060148684 ; 2006
71. Bunn P, Witta S. Methods of using saha and erlotinib for treating cancer. WO2007056244 ; 2007
72. Wang B. Compositions and methods for modulation of suppressor T cell activation. WO2007084775 ; 2007
73. Palladino M. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer. WO2008124699 ; 2008
74. Ordentlich P, Horobin J. Combination of er alpha+ ligands and histone deacetylase inhibitors for the treatment of cancer. WO2008058287 ; 2008
75. Steinbrecher A, Reinhold D, Quigley L, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGFbeta1 secretion in vivo. J Immunol 2001;166:2041
76. Ansorge S, Bank U, Nordhoff K, et al. Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases. US20070037752 ; 2007
77. Plato C. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions. WO2007100795 ; 2007
78. Leonard TW. Solid oral dosage form containing an enhancer. US20070292512 ; 2007
79. Kushner P, Goldfine ID, Hodges-gallagher L, et al. Small molecule potentiator of hormonal therapy for breast cancer. WO2008027837 ; 2008
80. Atadja PW, Bhalla KN, Manley PW. Combination of organic compounds. US20080200489 ; 2008
81. Pandey SC. Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism. WO2008042795 ; 2008
82. Van Quaquebeke E, Simon G, Van den hove L, et al. Napthalimide derivatives, methods for their production and pharmaceutical compositions therefrom. US20070117836 ; 2007
83. Van quaquebeke E, Simon G, El yazidi M, et al. 5-Urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer. WO2007128538 ; 2007
84. Van Quaquebeke E, Simon G, El Yazidi M, et al. Compositions and methods for treatment of prostate and breast cancer. US20090221628 ; 2009
85. Van Quaquebeke E, Simon G, El Yazidi M, et al. Compositions and methods for treatment of esophageal cancer. US20090232907 ; 2009
86. Brown DM. Naphthalimide compositions and uses thereof. US20070207977 ; 2007
87. Brown DM. Naphthalimide compositions and uses thereof. US20060211648 ; 2006
88. McCulloch W, Keegan M. Gemcitabine combination therapy. WO2007145704 ; 2007
89. McCulloch W. Deacetylase inhibitor therapy. WO2007146730 ; 2007
90. Lange N. Compounds for photochemotherapy. WO2007023398 ; 2007
91. Qazi GN, Saxena AK, Muthiah S, et al. Novel substituted 1H-benz [de] isoquinoline-1, 3-diones. WO2008084496 ; 2008
92. Imperiali B, Loving GS. Environmentally sensitive fluorophores. US20080206885 ; 2008
93. Vohra R, Dube G, Gan Z, et al. Methods of modulating neurotrophin- mediated activity. US20090082368 ; 2009
94. Huang S, Norton J, Appella D, et al. Anticancer compounds. WO2009089537 ; 2009
95. Wang W, Cheng W, Yang J. Method of inhibiting the growth of Helicobacter pylori. US20100305152 ; 2010